Lilly India enters autoimmune segment with Olumiant
Eli Lilly and Company (India) Pvt. Ltd. has announced the launch of Olumiant (baricitinib). This announcement has marked the company’s entry into the autoimmune segment in India. Olumiant (baricitinib) is a oncedaily oral medication for the treatment of adults with moderateto-severe active Rheumatoid Arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate. Olumiant is approved in more than 50 countries across the world. Despite the multiple options available for Rheumatoid Arthritis, there still exists an unmet need. More than half of the patients with moderateto-severe Rheumatoid Arthritis do not experience remission through conventional DMARDs. In clinical studies, Olumiant has demonstrated statistically significant improvements in a number of outcome measures including patient reported outcomes at various time points with rapid onset of action and sustained efficacy as well as superiority to standard of care at ACR 20 (American College of Rheumatology) and DAS (Disease Activity Score) 28 at 12 weeks.